Literature DB >> 27900409

Perspectives and challenges of antioxidant therapy for atrial fibrillation.

Iveta Gasparova1, Peter Kubatka2, Radka Opatrilova3, Martin Caprnda4, Slavomira Filipova5, Luis Rodrigo6, Leone Malan7, Ioana Mozos8, Miroslava Rabajdova9, Vladimir Nosal10, Nazarii Kobyliak11, Vanda Valentova2, Daniel Petrovic12, Mariusz Adamek13, Peter Kruzliak14,15.   

Abstract

Atrial fibrillation (AF) is the most common sustained arrhythmia associated with significant morbidity and mortality. The mechanisms underlying the pathogenesis of AF are poorly understood, although electrophysiological remodeling has been described as an important initiating step. There is growing evidence that oxidative stress is involved in the pathogenesis of AF. Many known triggers of oxidative stress, such as age, diabetes, smoking, and inflammation, are linked with an increased risk of arrhythmia. Numerous preclinical studies and clinical trials reported the importance of antioxidant therapy in the prevention of AF, using vitamins C and E, polyunsaturated fatty acids, statins, or nitric oxide donors. The aim of our work is to give a current overview and analysis of opportunities, challenges, and benefits of antioxidant therapy in AF.

Entities:  

Keywords:  Antioxidants; Atrial fibrillation; Atrial remodeling; Gene therapy; Oxidative stress; Prevention

Mesh:

Substances:

Year:  2016        PMID: 27900409     DOI: 10.1007/s00210-016-1320-9

Source DB:  PubMed          Journal:  Naunyn Schmiedebergs Arch Pharmacol        ISSN: 0028-1298            Impact factor:   3.000


  131 in total

1.  Atrial fibrillation--the growing epidemic.

Authors:  Gregory Y H Lip; Puneet Kakar; Timothy Watson
Journal:  Heart       Date:  2007-05       Impact factor: 5.994

2.  Regulation of macrophage cholesterol efflux through hydroxymethylglutaryl-CoA reductase inhibition: a role for RhoA in ABCA1-mediated cholesterol efflux.

Authors:  Carmen A Argmann; Jane Y Edwards; Cynthia G Sawyez; Caroline H O'Neil; Robert A Hegele; J Geoffrey Pickering; Murray W Huff
Journal:  J Biol Chem       Date:  2005-04-06       Impact factor: 5.157

3.  Statin use is associated with a reduction in atrial fibrillation after noncardiac thoracic surgery independent of C-reactive protein.

Authors:  David Amar; Hao Zhang; Paul M Heerdt; Bernard Park; Martin Fleisher; Howard T Thaler
Journal:  Chest       Date:  2005-11       Impact factor: 9.410

4.  Mechanisms of Hydrogen Peroxide-Induced Increase in Intracellular Calcium in Cardiomyocytes.

Authors: 
Journal:  J Cardiovasc Pharmacol Ther       Date:  1999-01       Impact factor: 2.457

5.  Defective cardiac ryanodine receptor regulation during atrial fibrillation.

Authors:  John A Vest; Xander H T Wehrens; Steven R Reiken; Stephan E Lehnart; Dobromir Dobrev; Parag Chandra; Peter Danilo; Ursula Ravens; Michael R Rosen; Andrew R Marks
Journal:  Circulation       Date:  2005-04-26       Impact factor: 29.690

6.  Atorvastatin Reduces the Incidence of Postoperative Atrial Fibrillation in Statin-Naive Patients Undergoing Isolated Heart Valve Surgery: A Double-Blind, Placebo-Controlled Randomized Trial.

Authors:  Mohammad Reza Dehghani; Majid Kasianzadeh; Yousef Rezaei; Nariman Sepehrvand
Journal:  J Cardiovasc Pharmacol Ther       Date:  2014-12-24       Impact factor: 2.457

7.  Atorvastatin improves peroxisome proliferator-activated receptor signaling in cardiac hypertrophy by preventing nuclear factor-kappa B activation.

Authors:  Anna Planavila; Juan C Laguna; Manuel Vázquez-Carrera
Journal:  Biochim Biophys Acta       Date:  2005-02-21

Review 8.  Primary and secondary prevention of atrial fibrillation with statins and polyunsaturated fatty acids: review of evidence and clinical relevance.

Authors:  Irene Savelieva; Antonios Kourliouros; John Camm
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2009-11-25       Impact factor: 3.000

9.  Preventive effects of fluvastatin in rat mammary carcinogenesis.

Authors:  Peter Kubatka; Nadežda Stollárová; Jozef Škarda; Katarína Žihlavníková; Karol Kajo; Andrea Kapinová; Katarína Adamicová; Martin Péč; Dušan Dobrota; Bianka Bojková; Monika Kassayová; Peter Orendáš
Journal:  Eur J Cancer Prev       Date:  2013-07       Impact factor: 2.497

10.  Prevalence, incidence, prognosis, and predisposing conditions for atrial fibrillation: population-based estimates.

Authors:  W B Kannel; P A Wolf; E J Benjamin; D Levy
Journal:  Am J Cardiol       Date:  1998-10-16       Impact factor: 2.778

View more
  15 in total

1.  Immune-inflammatory, oxidative stress and biochemical biomarkers predict short-term acute ischemic stroke death.

Authors:  Edna Maria Vissoci Reiche; Jair Roberto Gelinksi; Daniela Frizon Alfieri; Tamires Flauzino; Marcio Francisco Lehmann; Maria Caroline Martins de Araújo; Marcell Alysson Batisti Lozovoy; Andrea Name Colado Simão; Elaine Regina Delicato de Almeida; Michael Maes
Journal:  Metab Brain Dis       Date:  2019-03-14       Impact factor: 3.584

2.  Patient satisfaction after switching from warfarin to apixaban in patients with nonvalvular atrial fibrillation: AGAIN study.

Authors:  Yukihiro Koretsune; Takanori Ikeda; Ken Kozuma; Teruyuki Hirano; Masahiro Yasaka; Makoto Kida; Motohiko Chachin; Miki Imura
Journal:  Patient Prefer Adherence       Date:  2017-12-15       Impact factor: 2.711

Review 3.  Arrhythmogenic Substrates for Atrial Fibrillation in Obesity.

Authors:  Ellen R Lubbers; Morgan V Price; Peter J Mohler
Journal:  Front Physiol       Date:  2018-10-22       Impact factor: 4.566

4.  New-onset of postoperative atrial fibrillation is likely to recur in the absence of other triggers.

Authors:  Jesper Park-Hansen; Anders M Greve; Johan Clausen; Susanne J Holme; Christian L Carranza; Akhmadjon Irmukhamedov; Lubna Sabah; Qing Lin; Anne Sofie Madsen; Helena Domínguez
Journal:  Ther Clin Risk Manag       Date:  2018-09-07       Impact factor: 2.423

5.  COPD in patients after heart transplantation is associated with a prolonged hospital stay, early posttransplant atrial fibrillation, and impaired posttransplant survival.

Authors:  Rasmus Rivinius; Matthias Helmschrott; Arjang Ruhparwar; Bastian Schmack; Fabrice F Darche; Dierk Thomas; Tom Bruckner; Hugo A Katus; Philipp Ehlermann; Andreas O Doesch
Journal:  Clin Epidemiol       Date:  2018-09-27       Impact factor: 4.790

6.  Moderate chronic kidney disease and left atrial enlargement independently predict thromboembolic events and mortality in elderly patients with atrial fibrillation: a retrospective single-center study.

Authors:  Hai-Jun Wang; Kai-Liang Li; Jian Li; Kun Lin; Yang Shi; Hao Wang; Quan-Jin Si; Yu-Tang Wang
Journal:  J Int Med Res       Date:  2019-07-21       Impact factor: 1.671

7.  Gender Differences in the Association between Frailty, Cognitive Impairment, and Self-Care Behaviors Among Older Adults with Atrial Fibrillation.

Authors:  Youn-Jung Son; Kyounghoon Lee; Bo-Hwan Kim
Journal:  Int J Environ Res Public Health       Date:  2019-07-05       Impact factor: 3.390

8.  Chronic digitalis therapy in patients before heart transplantation is an independent risk factor for increased posttransplant mortality.

Authors:  Rasmus Rivinius; Matthias Helmschrott; Arjang Ruhparwar; Ann-Kathrin Rahm; Fabrice F Darche; Dierk Thomas; Tom Bruckner; Philipp Ehlermann; Hugo A Katus; Andreas O Doesch
Journal:  Ther Clin Risk Manag       Date:  2017-10-13       Impact factor: 2.423

9.  Examining Cardiomyocyte Dysfunction Using Acute Chemical Induction of an Ageing Phenotype.

Authors:  Said Masoud; Fraser McDonald; Dirk Bister; Claire Kotecki; Martin D Bootman; Katja Rietdorf
Journal:  Int J Mol Sci       Date:  2019-12-27       Impact factor: 5.923

10.  Elevated pre-transplant pulmonary vascular resistance is associated with early post-transplant atrial fibrillation and mortality.

Authors:  Rasmus Rivinius; Matthias Helmschrott; Arjang Ruhparwar; Bastian Schmack; Fabrice F Darche; Dierk Thomas; Tom Bruckner; Andreas O Doesch; Hugo A Katus; Philipp Ehlermann
Journal:  ESC Heart Fail       Date:  2020-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.